Immune response on outcomes in hepatocellular carcinoma

Norifumi Iseda, Shinji Itoh, Takahiro Tomiyama, Akinari Morinaga, Huanlin Wang, Tomonari Shimagaki, Takeshi Kurihara, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Tomohiro Iguchi, Tomoharu Yoshizumi, Masaki Mori

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Recently, immune checkpoint inhibitors (ICI) has been developed considerably. ICI has already been approved for malignant melanoma, lung cancer and renal cancer. We expected ICI to be taken for many cancers in the future. Therefore, the development of biomarker for them are needed. The recent large phase EI study IMbrave 150 evaluated atezolizumab plus bevacizumab vs sorafenib as the first treatment for patients with unresectable hepatocellular carcinoma (HCC). IMbrave 150 demonstrated statistically significant and clinically meaningful improvements in both OS and RFS for atezolizumab plus bevacizumab compared with sorafenib in HCC patients. A paradigm shift in the treatment of unresectable HCC is about to occur. In this article, we discussed the significance and biomarkers of tumor immunity in HCC microenvironment.

Original languageEnglish
Pages (from-to)1303-1306
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Issue number9
Publication statusPublished - Sept 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immune response on outcomes in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this